San Francisco-based startup, Nurix, Inc., which reportedly develops T-cellspecific immunosuppressants used to treat autoimmune diseases such as rheumatoid arthritis, lupus, multiple sclerosis, and psoriasis, has evidently secured $5.3 million in equity funding from four investors, according to a securities filing. Nurix is apparently backed by a group of venture investors, including The Column Group and Third Rock Ventures. See MedCity News, April 4, 2013.